Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 81

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 81
---
 may expedite the development or approval process, it does not change the standards for approval. If we apply for breakthrough
therapy designation or any other expedited program for our drug candidates, the FDA may determine that our proposed target indication
or other aspects of our clinical development plans do not qualify for such expedited program. Even if we are successful in obtaining
a breakthrough therapy designation or access to any other expedited program, we may not experience faster development timelines or achieve
faster review or approval compared to conventional FDA procedures. Access to an expedited program may also be withdrawn by the FDA if
it believes that the designation is no longer supported by data from our clinical development program. Additionally, qualification for
any expedited review procedure does not ensure that we will ultimately obtain regulatory approval for such drug candidate.

Risks Related to Our
Indebtedness

We have incurred significant
indebtedness, which will require substantial cash to service and which subjects us to certain financial requirements and business restrictions.

Since
2021, we issued $115,250,000 aggregate principal amount of senior notes due in part in 2026 and in 2027 (the “Notes”)
and in January 2026, debt in the amount of $107,500,000 principal amount under the Oaktree Loan becomes due. While the Company is
currently in discussions with its current senior secured lender and other potential lenders about refinancing the Oaktree Loan and
management believes it is probable that the Company will be able to refinance the Oaktree Loan based on the Company’s collateral strength and expected cash flows
from operations, there can be no assurance that the
Company will complete a refinancing on terms acceptable to it, or at all. We may incur additional indebtedness in the
future. Our ability to make scheduled payments on our indebtedness depends on our future performance and ability to raise additional
capital, which is subject to economic, financial, competitive and other factors, some of which are beyond our control. If we are
unable to generate sufficient cash to service our debt, we may be required to adopt one or more alternatives, such as selling
assets, restructuring our debt or obtaining additional capital through equity sales or incurrence of additional debt on terms that
may be onerous or highly dilutive to our stockholders. Our ability to engage in any of these activities would depend on the capital
markets and our financial condition at such time, and we may not be able to do so when needed, on desirable terms or